Drug intelligence / Profile preview

Penn Microbiome Therapy - 001

Development stage: Unknown
Lead developer: University of Pennsylvania
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Rectal

Overview

Penn Microbiome Therapy - 001 (PMT-001) is a fecal microbiota transplant (FMT) biologic product developed by the University of Pennsylvania for the treatment of severe and severe-complicated/fulminant Clostridium difficile infection (CDI). The therapy consists of a diverse community of live microorganisms derived from healthy donor stool, intended to restore a balanced intestinal microbiome and re-establish colonization resistance against C. difficile. It has been evaluated in Phase II clinical trials (NCT03970200) as an adjunctive treatment to standard antibiotic therapy to improve clinical outcomes in patients with life-threatening CDI.

Other names: Penn Microbiome Therapy 001

Beyond the preview

Go deeper on Penn Microbiome Therapy - 001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Penn Microbiome Therapy - 001.

Explore the full profile